fbpx

molecules of the month

AL-611

oral HCV NS5B polymerase inhibitor prodrug

preclin.candidate, discont.Õd due to compet.

from optimization of prior leads

J. Med. Chem., Sep. 24, 2020

Janssen BioPharma, South San Francisco, CA

Structure of AL-611
1 min read

AL-611 is a prodrug to a nucleoside inhibitor of HCV NS5B polymerase. While there have been very successful nucleoside drugs (e.g. sofosbuvir), several nucleoside inhibitors of HCV previously failed in the clinic due to severe toxicities, in some cases due to incorporation of the nucleosides into host RNA. The Janssen Biopharma (formerly Alios) team tried to navigate safety issues observed with other nucleosides by increasing the complexity of the sugar moiety. The presence of two fully-substituted, fluorine-bearing stereogenic carbons caught my eye. AL-611 is orally available in dogs and was selected as a drug candidate but discontinued due to the effectiveness of already approved drugs.


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: